ACADIA Pharmaceuticals (ACAD) Earnings Date, Estimates & Call Transcripts

$30.21 +0.03 (+0.10%)

Closing price 04:00 PM Eastern

Extended Trading

$30.37 +0.16 (+0.54%)

As of 07:59 PM Eastern

ACADIA Pharmaceuticals Earnings Summary

ACADIA Pharmaceuticals released Q2 2026 earnings on August 4, 2026, reporting an EPS of $0.18, which beat the consensus estimate of $0.07 by $0.11. Quarterly revenue rose 16.4% year-over-year to $308 million, above analyst estimates of $296.55 million. With a trailing EPS of $2.22 and a P/E Ratio of 13.61, ACADIA Pharmaceuticals' earnings are expected to grow 61.02% next year, from $0.59 to $0.95 per share.

Upcoming Q3 Earnings Date: Nov. 4After Market ClosesEstimated
Consensus EPS (Aug. 4): $0.07
Actual EPS (Aug. 4): $0.18 Beat By $0.11
Actual Revenue (Aug. 4): $308.00M

Q2 2026 Earnings Resources

ACAD Upcoming Earnings

ACADIA Pharmaceuticals' next earnings date is estimated for Wednesday, November 4, 2026, based on past reporting schedules.

Slide Deck

Full Screen Slide Deck

Get ACADIA Pharmaceuticals Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ACADIA Pharmaceuticals and other key companies, straight to your inbox.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ACAD Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

ACAD Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

ACADIA Pharmaceuticals Analyst EPS Estimates

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2026	2	-$0.01	$0.15	$0.07
Q2 2026	2	$0.01	$0.16	$0.09
Q3 2026	2	$0.15	$0.17	$0.16
Q4 2026	2	$0.18	$0.20	$0.19
FY 2026	8	$0.33	$0.68	$0.51
Q1 2027	1	$0.20	$0.20	$0.20
Q2 2027	1	$0.23	$0.23	$0.23

ACADIA Pharmaceuticals Earnings History by Quarter

Time Frame

Start Date

End Date

Export

Date	Quarter	Consensus Estimate	Reported EPS	Beat/Miss	GAAP EPS	Revenue Estimate	Actual Revenue	Details
11/4/2026 (Estimated)	-	-	-	-	-	-	-	-
8/4/2026	Q2 2026	$0.0682	$0.18	+$0.1119	$0.18	$296.55M	$308.00M
5/6/2026	Q1 2026	$0.04	$0.02	-$0.02	$0.02	$280.25M	$268.10M
2/26/2026	Q4 2025	$0.12	$1.60	+$1.48	$1.60	$292.54M	$298.00M
11/5/2025	Q3 2025	$0.14	$0.42	+$0.28	$0.42	$276.52M	$278.63M
8/6/2025	Q2 2025	$0.14	$0.16	+$0.02	$0.16	$263.07M	$264.57M
5/7/2025	Q1 2025	$0.10	$0.11	+$0.01	$0.11	$239.32M	$244.32M
11/6/2024	Q3 2024	$0.14	$0.20	+$0.06	$0.20	$248.83M	$250.40M

ACADIA Pharmaceuticals Earnings - Frequently Asked Questions

ACADIA Pharmaceuticals has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, November 4th, 2026 based off last year's report dates. Learn more on ACAD's earnings history.

ACADIA Pharmaceuticals issued an update on its FY 2026 earnings guidance on Tuesday, August, 4th. The company issued revenue guidance of $1.2 billion-$1.3 billion, compared to the consensus revenue estimate of $1.2 billion.

In the previous quarter, ACADIA Pharmaceuticals (NASDAQ:ACAD) reported $0.18 earnings per share (EPS) to beat the analysts' consensus estimate of $0.07 by $0.11. Learn more on analysts' earnings estimate vs. ACAD's actual earnings.

The conference call for ACADIA Pharmaceuticals' latest earnings report can be listened to online.
Listen to Conference Call

The conference call transcript for ACADIA Pharmaceuticals' latest earnings report can be read online.
Read Transcript

ACADIA Pharmaceuticals (NASDAQ:ACAD) has a recorded annual revenue of $1.07 billion.

ACADIA Pharmaceuticals (NASDAQ:ACAD) has a recorded net income of $391 million. ACAD has generated $2.22 earnings per share over the last four quarters.

ACADIA Pharmaceuticals (NASDAQ:ACAD) has a trailing price-to-earnings ratio of 13.61 and a forward price-to-earnings ratio of 51.20. The price/earnings-to-growth ratio is 22.24.

ACADIA Pharmaceuticals' earnings are expected to grow from $0.59 per share to $0.95 per share in the next year, which is a 61.02% increase.

More Earnings Resources from MarketBeat

Related Companies

Earnings Tools

Latest Articles

Earnings data for NASDAQ:ACAD is sourced from Fiscal.ai, with the most recent quarter reported on 8/4/2026. New results are added as companies report their earnings.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ACADIA Pharmaceuticals (ACAD) Earnings Date, Estimates & Call Transcripts